PROSPECTRA: “Protein Mass Spectrometry Analysis for Prostate Cancer Biomarkers Identification”
Prostate cancer is the second leading cause of cancer deaths in United States and Canada. The most widely used method for prostate cancer detection is the measurement of the prostate specific antigen (PSA). The PSA diagnostic test exhibits high sensitivity. However, its low specificity confines its use as an early detection biomarker. Mass Spectrometry (MS) data analysis helps on understanding the correlation between proteins/peptides and various diseases as well as the early cancer diagnosis. In most recent studies the correct classification rate between normal and cancerous MS cases is high; however, the identification of the protein subgroup, as they appear in MS spectrum, that provides the maximum separation and, at the same time, is connected to prostate cancer, so it could be used as a reliable biomarker for the specific disease, is still an open research field. In PROSPECTRA new methods will be developed to solve problems related to MS biosignals processing, using data available to the international research community, and a pattern recognition system will be developed for the classification between of normal and cancerous prostate MS spectrum, to estimate the possibility of locating possible biomarkers for prostate cancer.